Ipca Laboratories (IPCALAB) Q3 25/26 earnings summary

Executive summary

• Domestic business grew 12% in Q3 FY26, outpacing the Indian Pharmaceutical Market's 8.9% growth year-over-year.

• Export formulation business grew 17% in Q3 and 6% for the nine-month period; API business was flat in Q3 but up 14% for nine months.

• Standalone net total income for Q3 FY26 rose 11% year-over-year to Rs. 1,863.00 crores; consolidated net total income increased 7% to Rs. 2,412.69 crores.

• Standalone net profit for Q3 FY26 was Rs. 303.45 crores, up 13%; consolidated net profit was Rs. 326.27 crores, up 31%.

• Consolidated Q3 revenue was INR 2,245 crore, up 6.5% year-over-year; nine-month consolidated revenue grew 8.44% to INR 7,258 crore.

Financial highlights

• Standalone EBITDA margin improved to 26.09% in Q3 FY26 from 24.25% in Q3 FY25; consolidated EBITDA margin for Q3 FY26 was 22.15%, up from 19.87%.

• Standalone EPS for Q3 FY26 was Rs. 11.96 (up 13%); consolidated EPS was Rs. 12.86 (up 31%).

• For nine months FY26, standalone EBITDA margin was 25.15% (vs. 23.14%); consolidated EBITDA margin was 20.79% (vs. 19.18%).

• Standalone net profit for nine months FY26 was Rs. 870.23 crores (up 22%); consolidated net profit was Rs. 842.05 crores (up 26%).

• Material cost to sales ratio improved by 3.36 percentage points for nine months, driven by product mix and higher-margin business growth.

Outlook and guidance

• Expect overall company growth of 10%-11% annually, with promotional branded and generic businesses each targeting 10%-12% growth.

• EBITDA margin (ex-Unichem) expected to improve by 1.5% per year if top-line growth sustains at 10%-12%.

• Unichem's top-line expected to grow 8%-10% annually, with EBITDA margin targeted at 15% in 2-3 years, improving to 20% as filings and registrations mature.

• Management highlighted continued growth in both domestic and export markets, with strong performance in branded and generics segments.